Polymer Nanoparticle‐Mediated Delivery of Oxidized Tumor Lysate‐Based Cancer Vaccines

Cancer vaccination is a powerful strategy to combat cancer. A very attractive approach to prime the immune system against cancer cells involves the use of tumor lysate as antigen source. The immunogenicity of tumor lysate can be further enhanced by treatment with hypochlorous acid. This study explores poly(lactic‐co‐glycolic acid) (PLGA) nanoparticles to enhance the delivery of oxidized tumor lysate to dendritic cells. Using human donor‐derived dendritic cells, it is found that the use of PLGA nanoparticles enhances antigen uptake and dendritic cell maturation, as compared to the use of the free tumor lysate. The ability of the activated dendritic cells to stimulate autologous peripheral blood mononuclear cells (PBMCs) is assessed in vitro by coculturing PBMCs with A375 melanoma cells. Live cell imaging analysis of this experiment highlights the potential of nanoparticle‐mediated dendritic‐cell‐based vaccination approaches. Finally, the efficacy of the PLGA nanoparticle formulation is evaluated in vivo in a therapeutic vaccination study using B16F10 tumor‐bearing C57BL/6J mice. Animals that are challenged with the polymer nanoparticle‐based oxidized tumor lysate formulation survive for up to 50 days, in contrast to a maximum of 41 days for the group that receives the corresponding free oxidized tumor lysate‐based vaccine. Oxidized tumor lysate is a powerful source of antigens for cancer vaccination. This study has explored poly(lactic‐co‐glycolic acid) (PLGA) nanoparticles to enhance the dendritic cell uptake and immunostimulatory activity of oxidized tumor lysate. The PLGA‐based nanoparticles are evaluated in vitro using human donor‐derived dendritic cells and peripheral blood mononuclear cells, and in vivo in a therapeutic vaccination study using B16F10 tumor‐bearing C57BL/6J mice.